Abstract:Introduction: Most Colorectal Cancer (CRC)-related deaths are caused by metastatic disease, and more than 95% of CRC metastases (mCRC) are microsatellite stable (MSS) which respond poorly to Immune checkpoint inhibitors (ICI). Tumor-associated macrophages (TAMs) have been recognized as major drivers of immunoresistance in primary CRC; however, their role in mCRC remains poorly understood. We analyzed primary CRC and major metastatic sites (Liver, Peritoneum, Lungs) using single-cell RNA-sequencing (scRNAseq) to elucidate the TAM driven mechanisms of immunoresistance in the mCRC tumor microenvironment (TME) and used a novel TAM directed targeting strategy to improve responses to ICI in a preclinical orthotopic model of MSS-mCRC. Methods: Using scRNA-seq, we analyzed 22 samples from 14 patients with mCRC. Target antigens identified were validated using flow cytometry and immunofluorescence (IF). The antitumor activity of anti-TREM2 and anti-PD1 mABs was evaluated in-vivo using CT26 CRC cell line in BALB-C mice, assessing tumor immune response via flow cytometry. Results: We characterized the TME in MSS-mCRC and identified 17 clusters of malignant epithelial, immune, and stromal cells. Our sub-clustering analysis revealed 6 unique sub-populations of TAMs which were differentially distributed across liver, lung, and peritoneal metastases (PM).Two subsets of TAMs, 5 and 6, were enriched in PM and malignant ascites. TAMs 5/6 expressed canonical lipid-associated genes; TREM2, APOE, and PLTP. TREM2+ TAMs were also enriched in immunosuppressive and pro-angiogenic pathways, and expressed genes known to drive EMT and ECM remodeling in the TME. Thus, TREM2 was identified as a potential therapeutic target. We validated our transcriptomic findings using flow cytometry and IF analysis of MSS-mCRC showing an abundance of TREM2+ TAMs in PM. TREM2+ TAMs co-expressed CD163, known marker for M2-TAMs and stained positive for BODIPY. In an aggressive PM mouse model, treatment with anti-PD1, anti-TREM2, or combination anti-PD1/anti-TREM2 was insufficient to reduce tumor burden. However, a trend towards a reduction in total intratumoral F4/80+CD11b+ TAMs was observed in the combination treatment compared to other groups. All three treatments trended towards increased CD8+ intratumoral T-cell infiltration compared to control mice. Conclusion: Our study provides new insights into the TME of MSS-CRC metastases at a single-cell level. Our findings indicate that TREM2+ TAMs contribute to the immunosuppressive milieu of MSS-CRC metastases. Targeting TREM2 in combination with anti-PD1 resulted in a modulation of TME via reduction of TAMs paralleled by an increased infiltration of CD8+ T cells. This reprogramming of TME suggests that inhibiting TREM2 might augment response to ICI in MSS-CRC metastases, traditionally resistant to ICI. Citation Format: Muhammad Bilal Mirza, Matthew Alexander Cottam, Mustafa Raoof, Kamran Idrees. Deciphering the role of TREM2+ tumor-associated macrophages as mediators of immunoresistance in micro-satellite stable colorectal metastases [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 3718.

TREM2 deficiency reprograms intestinal macrophages and microbiota to enhance anti–PD-1 tumor immunotherapy

TREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing Anti-PD-1 Immunotherapy

The rationale of reprogramming TREM2+ macrophages for overcoming the resistance to immune checkpoint inhibitors in pancreatic adenocarcinoma.

Triggering Receptor Expressed on Myeloid Cells-2 (TREM-2) Elicited by Lung Cancer Cells to Facilitate Tumor Immune Evasion.

TREM2 inhibition triggers antitumor cell activity of myeloid cells in glioblastoma

Abstract 3718: Deciphering the role of TREM2+ tumor-associated macrophages as mediators of immunoresistance in micro-satellite stable colorectal metastases

TREM1 activation of myeloid cells promotes antitumor immunity

Immunosuppressive TREM2(+) macrophages are associated with undesirable prognosis and responses to anti-PD-1 immunotherapy in non-small cell lung cancer

TREM2 Deficiency Aggravates NLRP3 Inflammasome Activation and Pyroptosis in MPTP-Induced Parkinson's Disease Mice and LPS-Induced BV2 Cells

Abstract 6530: TREM1 inhibition: A novel approach to suppress tumor growth and enhance immune checkpoint therapy

TREM-1 Inhibition Restores Impaired Autophagy Activity and Reduces Colitis in Mice

Abstract 3555: TREM2 is Upregulated and Plays Oncogenic Role in Gastric Cancer

TREM-2 serves as a negative immune regulator through Syk pathway in an IL-10 dependent manner in lung cancer

Trem2 deficiency attenuates breast cancer tumor growth in lean, but not obese or weight loss, mice and is associated with alterations of clonal T cell populations

Triggering receptor expressed on myeloid cells-2 protects against polymicrobial sepsis by enhancing bacterial clearance.

Systematic analysis of TREM2 and its carcinogenesis in pancreatic cancer

TREM2 modulates microglia phenotypes in the neuroinflammation of Parkinson's disease

Alzheimer’s disease modification mediated by bone marrow-derived macrophages via a TREM2-independent pathway in mouse model of amyloidosis

TREM2 overexpression attenuates neuroinflammation and protects dopaminergic neurons in experimental models of Parkinson's disease.

Triggering Receptor Expressed on Myeloid Cells 2 Protects Dopaminergic Neurons by Promoting Autophagy in the Inflammatory Pathogenesis of Parkinson’s Disease

Abstract 5209: Generation of humanized TREM2 mice for preclinical evaluation of therapeutics targeting tumor-associated macrophages